pentixafor
Peptideexperimental
Clinical trial activity
18 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
9
Phase 3
1
Phase 4
0
Earliest trial started Nov 3, 2017 (NCT03335670)
Timeline
Indications
Studied for
- Cushing Syndrome · Phase 2
- Erdheim-Chester Disease · Early Phase 1
- Graft Rejection · Phase 2
- Heart Diseases · Phase 2
- Histiocytosis, Sinus · Early Phase 1
- Hyperaldosteronism · Phase 2
- Leukemia · Early Phase 1
- Lung Neoplasms · Early Phase 1
- Lymphoma · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 3
- Lymphoma, Non-Hodgkin · Early Phase 1
- Multiple Myeloma · Phase 2
- Myocarditis · Phase 2
- Neoplasms · Early Phase 1
- Neuroendocrine Tumors · Early Phase 1
- Thymoma · Early Phase 1
Mechanism of action
- C-X-C chemokine receptor type 4INHIBITOR
CXCR4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 68-Gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07007325 | Early Phase 1 (Phase 1) | Sep 15, 2025 | Institut de Cancerologie de l'Ouest Paul Papin |
| NCT06871176 | N/A | Mar 4, 2025 | University of Toronto |
| NCT06246357 | Phase 2 | Sep 23, 2024 | National Cancer Institute (NCI) |
| NCT06478875 | Phase 2 | Jun 30, 2024 | Assistance Publique - Hôpitaux de Paris, Pentixapharm AG |
| NCT06773663 | Phase 1/Phase 2 (Phase 2) | Dec 30, 2023 | Chinese Academy of Medical Sciences |
| NCT06125028 | Phase 3 | Dec 15, 2023 | Pentixapharm AG, Pivotal S.L. |
| NCT06132737 | Phase 1/Phase 2 (Phase 2) | Nov 7, 2023 | Pentixapharm AG, University of Duisburg-Essen |
| NCT06086327 | Early Phase 1 (Phase 1) | Jun 22, 2023 | Chinese Academy of Medical Sciences, Tsinghua University |
| NCT05499637 | Phase 2 | Nov 15, 2022 | University of Lausanne |
| NCT05222269 | Phase 2 | Oct 5, 2022 | Eckert & Ziegler Radiopharma GmbH |
| NCT05321862 | Phase 2 | Sep 30, 2022 | University of Nantes |
| NCT05255926 | N/A | Mar 1, 2022 | Xiamen University |
| NCT05093335 | Early Phase 1 (Phase 1) | Oct 1, 2021 | Memorial Sloan-Kettering Cancer Center |
| NCT05364177 | Early Phase 1 (Phase 1) | Aug 11, 2021 | Chinese Academy of Medical Sciences |
| NCT04561492 | Phase 2 | Dec 1, 2020 | University of Nantes |
| NCT04504526 | Early Phase 1 (Phase 1) | Aug 31, 2020 | Fujian Medical University |
| NCT03436342 | Early Phase 1 (Phase 1) | Jun 1, 2018 | Chinese Academy of Medical Sciences |
| NCT03335670 | Early Phase 1 (Phase 1) | Nov 3, 2017 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of Iowa |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 4 | 4 | 2 | 2018 |
| Pentixapharm AG | For profit | 3 | 2 | 2 | 2023 |
| National Cancer Institute (NCI) | Government | 2 | 1 | 2 | 2017 |
| University of Nantes | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Eckert & Ziegler Radiopharma GmbH | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Institut de Cancerologie de l'Ouest Paul Papin | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2017 |
| Pivotal S.L. | For profit | 1 | 0 | 1 | 2023 |
| Tsinghua University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Duisburg-Essen | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Iowa | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Lausanne | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Xiamen University | Academic/Hospital | 1 | 1 | 1 | 2022 |
17 organizations
Page 1 / 1